Johnson & Johnson agreed to acquire mental-illness drug developer Intra-Cellular Therapies for about $15 billion.
Johnson & Johnson said Monday it expects to accelerate sales growth beyond Wall Street expectations in the field of ...
Wells Fargo analyst Larry Biegelsen has maintained their neutral stance on JNJ stock, giving a Hold rating yesterday.Stay Ahead of the ...
Johnson & Johnson remains a Buy for its stability and consistent dividends, despite short-term price fluctuations and modest ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Johnson & Johnson MedTech has temporarily paused all U.S. external evaluations and cases using its Varipulse pulse field ...
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf ...